In a significant development in the future of oncology, Eli Lilly and Co. announced a definitive agreement to buy Kelonia Therapeutics for up to $7 billion. This acquisition makes Lilly one of the key players in disrupting the oncology strategy through CAR-T therapy, allowing for administration via an off-the-shelf injection vs. the expensive and time-consuming in vitro manufacturing process.
The Disruption: Eliminating the Bottlenecks of Traditional CAR-T
What’s different about this acquisition is Kelonia’s iGPS (in-vivo Gene Placement System) is that all CAR-T therapies today use “ex vivo” modification, where the patient’s cells are extracted, genetically modified in a lab, and then reinfused. Whereas Kelonia’s platform uses lentiviral vectors to modify T-cells directly within the patient’s body into CAR-T cells.
With KLN-1010, Lilly believes they have identified the first-in-class in vivo treatment for relapsed/refractory multiple myeloma patients. Following clinical validation of KLN-1010 at the 2025 American Society of Hematology Annual Meeting, the program demonstrated that it was possible to achieve deep remission while avoiding standard toxicities associated with chemotherapy prior to CAR-T administration.
The Bigger Play: Building a Platform Beyond Myeloma
This acquisition is not just about multiple myeloma; it is a strategic move to own a scalable delivery engine.
- Democratization of Care: Lilly aims to move cell therapy beyond specialized academic centers into community hospitals through a one-time intravenous gene therapy approach.
- Platform Versatility: The iGPS® technology is designed for broad applicability, signaling Lilly’s intent to extend in vivo engineering to solid tumors and autoimmune diseases, where traditional CAR-T has struggled to scale.
The acquisition of Kelonia represents much more than simply adding another product line to Lilly’s portfolio but integrating a scalable delivery mechanism. Lilly, with this deal, aims to:
Democratize Cancer Treatment: By moving cell therapy beyond academic centers into community hospitals through a one-time intravenous gene therapy approach. Make iGPS Platform Versatile: By broadening the application of the platform beyond myeloma, targeting solid tumors and autoimmune diseases, where CAR-T has had difficulty scaling.
Diving into the Billion-Dollar Race for CAR-T Therapy Dominance
Lilly’s bet is the latest move in an intensifying global race as pharmaceutical giants secure next-generation cell therapy assets to future-proof their portfolios.
Before this acquisition announcement, Gilead Sciences announced its acquisition of Arcellx for $7.8 billion. Last year, Bristol Myers Squibb confirmed to acquire Orbital Therapeutics, a privately held biotechnology company specializing in RNA medicines and in vivo CAR T-cell therapies. Also, Novartis has teamed with Relation Therapeutics, a London-based biotechnology company, to access the latter’s AI-powered platform for identifying, validating, and advancing potential first-in-class targets in atopic diseases.
The direction is clear.
The industry is moving from complex, individualized therapies toward scalable, off-the-shelf, in vivo solutions.
IeB Perspective: Who’s Next in the In-Vivo Race?
As the industry shifts from “cell-as-a-drug” to “vector-as-a-drug,” several startups are emerging as high-value acquisition targets:
- Umoja Biopharma: Its VivoVec™ platform, backed by FDA Fast Track status, positions it as a strong contender for companies like Sanofi and Roche.
- Sana Biotechnology: Its fusosome-based delivery system, advancing toward 2026 milestones, could be the “missing piece” for Novartis’s next-gen pipeline.
- Ensoma: Focused on in vivo engineering of hematopoietic stem cells, offering a system-wide approach that may attract AbbVie and Bristol Myers Squibb.
Conclusion: For Lilly, this is not just about treating multiple myeloma. It is about owning the delivery system that could define the next era of cancer and autoimmune therapy.
